by Lisa Willemse | May 24, 2013
Co-authored with Dr. Zubin Master, Assistant Professor at the Alden March Bioethics Institute, Albany Medical College and Research Associate at the University of Alberta’s Health Law and Science Policy Group. In the current discussion about the now controversial...
by David Brindley | Apr 22, 2013
. Within the past few weeks, we have all lost someone who has impacted our lives. And this I can guarantee. On Monday 8th April 2013, I woke up, grabbed my tennis bag and headed for a morning hit. In the car, I heard the lacquered voice of the BBC’s John Humphrys...
by Ben Paylor | Apr 3, 2013
Why should stem cell researchers use Twitter? Powerful news aggregator/information filter Able to engage/converse with other attendees at conferences & meetings Increase traffic, discussion and citations of your papers Create professional networks and...
by David Brindley | Mar 19, 2013
. Part 5 in Cell Therapy Industry 2027 series A short time ago, I had the immense pleasure of driving through the Napa Valley bathed in a warm pastel sunset. The view was accompanied by a two-chord soundtrack: the reassuring chinking of several bottles of the...
by Paul Krzyzanowski | Mar 13, 2013
[pullquote]In time, this purchase might make BioTime the company that Geron was supposed to be.[/pullquote]Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some...
by Ubaka Ogbogu | Feb 26, 2013
Patients contemplating medical travel for the purpose of receiving scientifically unproven stem cell treatments may wish to consider one more potential side effect: the possibility of losing their eligibility for health status-related compensation and benefits. In May...
Comments